MedTrace Logo

A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha

NCT06547840 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-06

No results posted yet for this study

Summary

EPS101-10-02 is a Phase Ib open label, multicentre clinical trial comprising of a Dose Escalation phase (Part 1) followed by a Dose Expansion phase (Part 2) of MOv18 IgE in patients with folate receptor alpha-expressing (5% or higher) platinum resistant ovarian cancer

The dose escalation part of the study will primarily assess the safety and tolerability of MOv18 IgE in ascending dose cohorts, until the determination of the maximum tolerated dose (MTD) or maximum administered dose (MAD).

Part 2 (dose expansion) will further assess the safety, tolerability and anti-tumour activity of MOv18 IgE.

Conditions

Interventions

DRUG

MOv18 IgE

MOv18 IgE is an anti-FRα monoclonal antibody (mAb) of the IgE class

Sponsors & Collaborators

  • Epsilogen Ltd

    lead INDUSTRY

Principal Investigators

  • Rebecca Kristeleit, MD · Guy's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-03
Primary Completion
2026-07-31
Completion
2027-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06547840 on ClinicalTrials.gov